Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Outcomes of eltrombopag combined with immunosuppressive therapy in adults with severe aplastic anemia: A large, propensity-matched retrospective analysis

Mostafa Eysha, Manas Pustake, Bayan Khasawneh et al. Nov 03, 2025 pp. 3201-3201 10.1182/blood-2025-3201

Abstract Background: The addition of eltrombopag (EPAG) to standard immunosuppressive therapy (IST) has improved hematologic response rates i...

Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications

Alberto Guijosa, Nickolas Tsakmaklis, Margaret Kobs et al. Nov 03, 2025 pp. 3577-3577 10.1182/blood-2025-3577

Abstract Introduction: Venetoclax and pirtobrutinib are two novel targeted agents used for the treatment of relapsed or refractory Waldenströ...

Trends in mortality and comorbidity of multiple myeloma among u.S. adults with stroke: A CDC wonder-based analysis, 1999–2023

Muhammad Umar, Khushbakht Shah, Nayanika Tummala et al. Nov 03, 2025 pp. 8147-8147 10.1182/blood-2025-8147

Abstract Background : Multiple Myeloma, a malignancy of the plasma cells remains one of the reasons for widespread morbidity and mortality....

Explainable AI-based prediction of chronic kidney disease as a long-term outcome of sickle cell disease in a large, multi-site observational data cohort

Biree Andemariam, Kathleen Torres, Joseph Romano Nov 03, 2025 pp. 2967-2967 10.1182/blood-2025-2967

Abstract Introduction Sickle cell disease (SCD) is a hereditary hemolytic anemia due to abnormal polymerization of intra-erythrocytic hemogl...

Disparities and reversal of declines: A 22-year analysis of mortality trends in patients with concurrent anemia and heart failure in the United States (1999–2020)

FNU Deeksha, Muhammad Umer, Manpreet Saini et al. Nov 03, 2025 pp. 6450-6450 10.1182/blood-2025-6450

Abstract Introduction Anemia is a common comorbidity among patients with heart failure (HF), associated with worse funct...

Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Adam Braun, Nancy Bartlett, Dai Chihara et al. Nov 03, 2025 pp. 6261-6261 10.1182/blood-2025-6261

Abstract Background: Mosunetuzumab (Mosun) is a CD20xCD3 bispecific antibody (BsAb) evaluated in patients (pts) with B-cell non-Hodgkin lymp...

Etavopivat in adolescents with sickle cell disease: Emerging safety and efficacy findings from the first cohort of the ongoing Phase 1/2 hibiscus kids study

Adlette Inati, Bernhards Ogutu, E. Leila Jerome Clay et al. Nov 03, 2025 pp. 618-618 10.1182/blood-2025-618

Abstract Background: Etavopivat is a selective, orally bioavailable, small-molecule activator of the pyruvate kinase red blood cell (RBC) is...

Machine learning accurately predicts mortality in adult NPM1-mutant Acute Myeloid Leukemia using baseline clinical and genomic features

Rahul Thakur, Sophie Thieme, Marcus Dempster et al. Nov 03, 2025 pp. 6116-6116 10.1182/blood-2025-6116

Abstract Introduction Nucleophosmin1-mutated (NPM1m) acute myeloid leukemia (AML) accounts for ~30% of adult AML and is generally considered...

Using electronic consultations to identify hematology education needs in primary care

Saumya Bansal, Sapna Humar, Claire Sethuram et al. Nov 03, 2025 pp. 4641-4641 10.1182/blood-2025-4641

Abstract BackgroundTopics covered in primary care Continuing Professional Development (CPD) activities often do not reflect the real-world l...

A dangerous convergence: Long-term mortality trends in aplastic anemia and sepsis (1999-2023)

Nafila Zeeshan, Swapna Gangasani, Nayanika Tummala et al. Nov 03, 2025 pp. 6453-6453 10.1182/blood-2025-6453

Abstract Background: Aplastic anemia (AA), a rare hematologic disorder characterized by pancytopenia and bone marrow failure, poses a high r...

Sarcopenia and body composition predict survival and reveal immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma

Thomas Wiemers, Michael Rade, Nora Grieb et al. Nov 03, 2025 pp. 7676-7676 10.1182/blood-2025-7676

Abstract Introduction: Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed/refra...

Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements

Yanjing Liu, Li Chai, Devendra Hiwase et al. Nov 03, 2025 pp. 3231-3231 10.1182/blood-2025-3231

Abstract Epigenetic reprogramming, particularly aberrant DNA methylation, drives many myeloid malignancies. While some patients have identif...

Rhoifolin, an inhibitor targeting the ALDH2-PKC delta axis, eradicates MRD in chronic myeloid leukemia by eliminating leukemia stem cells

Xiuying Hu, JiShi Wang Nov 03, 2025 pp. 7847-7847 10.1182/blood-2025-7847

Abstract Background: Chronic myeloid leukemia (CML) patients frequently develop minimal residual disease (MRD) following tyrosine kinase inh...

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Yumeng Zhang, Fatima Tuz Zahra, Daniel DeAvila et al. Nov 03, 2025 pp. 2767-2767 10.1182/blood-2025-2767

Abstract Introduction The CD20xCD3 bispecific antibodies (BsAbs), epcoritamab (Epco) and glofitamab (Glofi), have emerged as effective thera...

Long-read single-cell isoform sequencing for cell type-specific detection of genomic rearrangement-dependent and -independent fusion transcripts

Wencke Walter, Wolfgang Kern, Anna Stengel Nov 03, 2025 pp. 6117-6117 10.1182/blood-2025-6117

Abstract Background: Fusion transcripts are formed by combining exons from two different genes, often due to structural rearrangements such...

Why are mice lymphocytic and primates granulocytic? an evo-devo approach to granulopoiesis

Eliezer Yampel, Marta Iwanaszko, Hrishikesh Mehta et al. Nov 03, 2025 pp. 1220-1220 10.1182/blood-2025-1220

Abstract Neutrophils play a critical role as first-line, non-specific responders in the innate immune system. They are characterized by thei...

Cannabinoid exposure in utero exacerbates hyperalgesia in offspring of sickle mice

Donovan Argueta, Reina Lomeli, Kristen Peterson et al. Nov 03, 2025 pp. 9-9 10.1182/blood-2025-9

Abstract Approximately 5% of pregnant women in the United States and 20% of pregnant women aged 18-24 years in California reported using can...

Outcomes of omidubicel-expanded umbilical cord blood transplantation in patients with severe aplastic anemia

Richard Childs, Xin Tian, Neal Young et al. Nov 03, 2025 pp. 5963-5963 10.1182/blood-2025-5963

Abstract Introduction Severe Aplastic Anemia (SAA) is a life-threatening disorder characterized by bone marrow failure, pancytopenia, infect...

Pediatric-inspired regimens for ALL are not associated with improved overall survival in US hispanic adult patients

Alexander Krule, Ryan Sun, Ahmad Nassar et al. Nov 03, 2025 pp. 2731-2731 10.1182/blood-2025-2731

Abstract Background: Adult ALL outcomes have significantly improved with the adoption of pediatric inspired regiments (PIR). However, these...

CSF-1R+ macrophages orchestrate human skin chronic graft-versus-host disease

Julie Boiko, Daniel Jones, Anna Elz et al. Nov 03, 2025 pp. 588-588 10.1182/blood-2025-588

Abstract Skin is the most frequently involved organ in chronic graft-versus-host disease (cGVHD) and presents as superficial lichenoid lesio...

A prospective, multicenter study on stem cell mobilization using EAP regimen as first-line mobilization in patients with multiple myeloma and lymphoma

Peipei Ye, Weiying Feng, Linjie Li et al. Nov 03, 2025 pp. 4179-4179 10.1182/blood-2025-4179

Abstract Background: The optimal stem cell mobilization strategy in multiple myeloma (MM) and lymphoma remains debatable. We evaluated the e...

Targeting PRMT7 enhances the anti-AML immunity by regulating MHC-I

Shuaishuai Ge, Kaixiu luo, Lei Zhang et al. Nov 03, 2025 pp. 387-387 10.1182/blood-2025-387

Abstract Protein arginine methylation regulates several cellular functions, including RNA splicing, translation and DNA damage repair. Prote...

The development of FT839: An off-the-shelf CD19xCD38 dual-CAR T cell for the treatment of multiple myeloma

Spas Markov, John Reiser, Brian Groff et al. Nov 03, 2025 pp. 7631-7631 10.1182/blood-2025-7631

Abstract Following autologous chimeric antigen receptor (CAR) T-cell therapy, approximately 50% of multiple myeloma (MM) patients relapse wi...

Outcome of bridging therapy in chimeric antigen receptor T cell treatment for Relapsed/Refractory B-cell non-Hodgkin lymphoma: A retrospective study.

Sanfang Tu, Langqi Wang, Shaojie Wu et al. Nov 03, 2025 pp. 8045-8045 10.1182/blood-2025-8045

Abstract Background: The CD19-targeted chimeric antigen receptor T (CAR-T) cell therapy has achieved significant efficacy in the treatment o...

Characterization of hemophagocytic lymphohistiocytosis (HLH) in an urban population: Demographics, associated risk factors, and identifying areas for improvement

Safia Ansari, Kristy Bono, Merry Zhai et al. Nov 03, 2025 pp. 6543-6543 10.1182/blood-2025-6543

Abstract Introduction Hemophagocytic Lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome characterized by exces...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page